BUZZ-Adial Pharma jumps on regulatory pathway for alcohol-use disorder drug

Shares of drug developer Adial Pharmaceuticals ADIL.O rise as much as 68.8% to $1.30

ADIL says U.S. FDA agreed with co's plan to use a specific approach called "in vitro bridging strategy" to support the development of AD04, to treat alcohol-use disorder in heavy-drinking patients

This approach involves using existing data and lab tests to show that the new version of AD04 is equivalent to the previous version

Co is developing the drug for its upcoming late-stage trial, set to begin this year

Last year, AD04 showed safety and tolerability consistent with an existing treatment

ADIL fell 42.3% in 2024